Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trilaciclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 16/20 | 1.00 |
| ▸ | CDK6 known ✓ | Q00534 | 3/20 | 1.00 |
| ▸ | CDK2 | P24941 | 20/20 | 1.00 |
| ▸ | CCND1 | P24385 | 16/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 9/20 | 1.00 |
| ▸ | CCND3 | P30281 | 3/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 2/20 | 1.00 |
| ▸ | CDK9 | P50750 | 2/20 | 1.00 |
| ▸ | TTK | P33981 | 1/20 | 0.83 |
| ▸ | FLT3 | P36888 | 1/20 | 0.83 |
| ▸ | CCNH | P51946 | 1/20 | 0.83 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.83 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.83 |
| ▸ | NUAK2 | Q9H093 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trilaciclib SCHEMBL29356370 | 1.00 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29763763 | 1.00 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29514690 | 0.99 | CDK2 (0.98) | CDK2CDK4CCND1CCNE1CCND3 | |
| Trilaciclib SCHEMBL29375833 | 0.99 | CDK2 (0.98) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL4549924 | 0.99 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL10082029 | 0.93 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22551643 | 0.93 | CDK2 (1.00) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL20959535 | 0.92 | CDK2 (0.86) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL20959189 | 0.91 | CDK2 (0.84) | CDK2CDK4CCND1CCNE1CCND3 | |
| SCHEMBL22005227 | 0.91 | CDK2 (0.84) | CDK2CDK4CCND1CCNE1CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240043539-A1 | METHODS OF INDUCING AN IMMUNOMODULATORY TUMOR RESPONSE | CORNELL UNIVERSITY | 2024-02-08 | — | — | US | claimed |
| EP-4259659-A1 | METHODS OF INDUCING AN IMMUNOMODULATORY TUMOR RESPONSE | Cornell University (US) | 2023-10-18 | — | — | EP | claimed |
| EP-3503923-B1 | COMBINATION THERAPIES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | EISAI R&D MAN CO LTD (JP) | 2023-10-04 | — | — | EP | claimed |
| EP-4218820-A2 | COMBINATION THERAPIES FOR THE TREATMENT OF BREAST CANCER | Eisai R&D Management Co., Ltd. (JP) | 2023-08-02 | — | — | EP | claimed |
| US-20230158048-A1 | COMBINATIONS | RECURIUM IP HOLDINGS, LLC | 2023-05-25 | — | — | US | claimed |
| EP-4106760-A1 | COMBINATIONS | Recurium IP Holdings, LLC (US) | 2022-12-28 | — | — | EP | claimed |
| WO-2022125652-A1 | METHODS OF INDUCING AN IMMUNOMODULATORY TUMOR RESPONSE | CORNELL UNIVERSITY (US) | 2022-06-16 | — | — | WO | claimed |
| WO-2021226263-A1 | COMBINATIONS | RECURIUM IP HOLDINGS, LLC (US) | 2021-11-11 | — | — | WO | claimed |
| US-11083722-B2 | Combination therapies for the treatment of breast cancer | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-08-10 | — | — | US | claimed |
| US-20210113537-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF BREAST CANCER | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-04-22 | — | — | US | claimed |
| US-20190175598-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-06-13 | — | — | US | claimed |
| US-20260041695-A1 | COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER | GENENTECH, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| US-12534472-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | PHARMACOSMOS HOLDING A/S (DK) | 2026-01-27 | — | — | US | disclosed |
| US-12534472-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | PHARMACOSMOS HOLDING A/S (DK) | 2026-01-27 | — | — | US | disclosed |
| US-12497404-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | PHARMACOSMOS HOLDING A/S (DK) | 2025-12-16 | — | — | US | disclosed |
| US-20130237544-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237544-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237534-A1 | CDK INHIBITORS | G1 THERAPEUTICS, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| WO-2012061156-A1 | CDK INHIBITORS | TAVARES FRANCIS X (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130237534-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | CDK4 12/4885CDK6 3/4885CDK2 5/4885 |
| US-20230158048-A1 | COMBINATIONS | CDK4, CDK6, CDKL4 | CDK4 1/4885CDK6 2/4885CDK2 8/4885 |
| US-20260041695-A1 | COMBINATION THERAPIES FOR TREATMENT OF BREAST CANCER | PIK3CA, CDK4, CDK3 | CDK4 2/4885CDK6 28/4885CDK2 13/4885 |
| US-20240043539-A1 | METHODS OF INDUCING AN IMMUNOMODULATORY TUMOR RESPONSE | ICOS, IFNG, MYD88 | CDK4 2564/4885CDK6 2715/4885CDK2 3709/4885 |
| US-20210113537-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF BREAST CANCER | CDK4, CDK6, CDKL4 | CDK4 1/4885CDK6 2/4885CDK2 17/4885 |
| US-20190175598-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | CDKL4, CDK4, ERBB4 | CDK4 2/4885CDK6 5/4885CDK2 24/4885 |
| US-12497404-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | MCL1, ETV6, ALK | CDK4 20/4885CDK6 37/4885CDK2 50/4885 |
| US-11083722-B2 | Combination therapies for the treatment of breast cancer | CDK4, CDK6, CDKL4 | CDK4 1/4885CDK6 2/4885CDK2 17/4885 |
| US-12534472-B2 | Morphic forms of trilaciclib and methods of manufacture thereof | CTNND1, FLT3, MEF2D | CDK4 129/4885CDK6 296/4885CDK2 153/4885 |
| US-20130237544-A1 | CDK INHIBITORS | CDK3, CDK9, CDK6 | CDK4 12/4885CDK6 3/4885CDK2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.